Andrew McRae

McRae is the emergency department representative for the AHS COVID-19 Scientific Advisory Group under Alberta Health Services.¹⁾

McRae is an Editorial Fellow at the Canadian Medical Association Journal.^{2) 3)}

In this capacity, McRae co-authored an editorial titled “SARS-CoV-2 vaccination should be required to practise medicine in Canada".⁴⁾

McRae is a collaborator on a project that addresses ethical and policy challenges posed by cluster randomized trials, in partnership with the Rotman Institute of Philosophy and the Ottawa Hospital Research Institute, funded by the Canadian Institutes of Health Research.⁵⁾

The OHRI has received funding for research from Pfizer for research on drugs for advanced lung cancer,⁶⁾ kidney transplant patients^{7) 8)} and blood clots in cancer patients.^{9) 10)}

Bristol-Myers Squibb also funded the latter study, as did CanVECTOR, which is funded by Alexion, Aniara Diagnostica, Aspen Pharmacare, Bayer, bioMérieux, Boston Scientific, Bristol-Myers Squibb, Cardinal Health, Daiichi Sankyo, LEO Pharma, Pfizer, and Sanofi.¹¹⁾

Another study looking at blood thinners in pregnancy was also funded by Pfizer, as well as Eli Lilly.^{12) 13)}

Other pharmaceutical research funders are AstraZeneca,¹⁴⁾ Janssen,¹⁵⁾ and GlaxoSmithKline.¹⁶⁾

McRae is a Researcher and Assistant Professor at the University of Calgary's Department of Emergency Medicine, a partnership between Alberta Health Services and the Cumming School of Medicine.¹⁷⁾ He has a cross-appointment to the Department of Community Health Sciences. In addition to active research interests in emergency department crowding and operations, his primary interest is in health services dimensions of the diagnosis and treatment of cardiovascular emergencies (myocardial infarction, arrhythmias, stroke).

McRae was a Postdoctoral Fellow at the Rotman Institute of Philosophy at Western University from 2009 – 2011.¹⁸⁾

McRae received an unrestricted research grant from Roche for 2021-2022.¹⁹⁾